Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.50 |
| ▸ | KRAS | P01116 | 7/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | HRAS | P01112 | 1/20 | 0.49 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168617 | 0.97 | TFPI (0.53) | TFPIF2RXFP1PTH1RKRAS | |
| SCHEMBL16299147 | 0.91 | RXFP1 (0.56) | TFPIF2RXFP1PTH1RKRAS | |
| SCHEMBL10169113 | 0.88 | RXFP1 (0.59) | TFPIRXFP1KRAS | |
| SCHEMBL10168283 | 0.88 | RXFP1 (0.59) | TFPIRXFP1KRAS | |
| SCHEMBL10168809 | 0.88 | RXFP1 (0.59) | TFPIRXFP1KRAS | |
| SCHEMBL15470451 | 0.86 | TFPI (0.62) | TFPIKRASHRASSOS1 | |
| SCHEMBL10168790 | 0.86 | RXFP1 (0.57) | TFPIRXFP1PTH1RKRASKEAP1 | |
| SCHEMBL10168791 | 0.86 | RXFP1 (0.57) | TFPIRXFP1PTH1RKRASKEAP1 | |
| SCHEMBL10168608 | 0.86 | RXFP1 (0.57) | TFPIRXFP1PTH1RKRASKEAP1 | |
| SCHEMBL10168624 | 0.86 | RXFP1 (0.57) | TFPIRXFP1PTH1RKRASKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | TFPI 2851/4885F2 4437/4885RXFP1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.